Synthesis and Biological Evaluation of Chromenylurea and Chromanylurea Derivatives as Anti-TNF-α agents that Target the p38 MAPK Pathway

Identification, Synthesis, and Biological Evaluation of 6-[(6R)-2-(4-Fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a Potent p38 MAP Kinase Inhibitor

(2012) Toru Asano et al.   JOURNAL OF MEDICINAL CHEMISTRY

Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury

(2011) Praveen Anand et al.   EUROPEAN JOURNAL OF PAIN

A possible mechanism for hepatotoxicity induced by BIRB-796, an orally active p38 mitogen-activated protein kinase inhibitor

(2011) Shunsuke Iwano et al.   JOURNAL OF APPLIED TOXICOLOGY

The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796

(2010) Justin Dietrich et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections

(2009) Keith Kirkwood et al.   CURRENT DRUG METABOLISM

A Randomized, Placebo-Controlled Study of the Effects of the p38 MAPK Inhibitor SB-681323 on Blood Biomarkers of Inflammation in COPD Patients

(2009) Dave Singh et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Short Synthesis of 1-(3-tert-Butyl-1-phenyl-1H-pyrazol-5-yl)-3-(5-(2-morpholinoethoxy)-2H-chromen-8-yl) Urea Derivatives

(2009) Xingzhou Li et al.   SYNTHETIC COMMUNICATIONS

p38MAPK: stress responses from molecular mechanisms to therapeutics

(2009) Lydia R. Coulthard et al.   TRENDS IN MOLECULAR MEDICINE